Susceptibility to myeloid and lymphoid leukemia is mediated by distinct inhibitory KIR-HLA ligand interactions.
Verheyden
S
S
Demanet
C
C
D015235:HLA-B Antigens / Q000502:physiology*; D015236:HLA-C Antigens / Q000502:physiology*; D006801:Humans; D007694:Killer Cells, Natural / Q000276:immunology*; D007945:Leukemia, Lymphoid / Q000276:immunology*; D007951:Leukemia, Myeloid / Q000276:immunology*; D011971:Receptors, Immunologic / Q000502:physiology*; D054340:Receptors, KIR; D019139:Tumor Escape
D015235:HLA-B Antigens; D015236:HLA-C Antigens; D011971:Receptors, Immunologic; D054340:Receptors, KIR